Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepati...(ng capital. As well Raptor's products ma...)

Date:10/12/2009

ng capital. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009; Raptor's annual report on Form 10-K filed with the SEC on March 27, 2009; Raptor's quarterly report on Form 10-Q filed with the SEC on August 11, 2009; Raptor's wholly-owned subsidiary's, Raptor Pharmaceuticals Corp. ("RPC") Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; RPC's annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and RPC's quarterly report on Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.

    For more information, please contact:

    Karl Cahill, Investor Relations
    (858) 531-6100
    kcahill@raptorpharma.com

    The Ruth Group
    Sara Ephraim Pellegrino (investors)
    (646) 536-7002
    '/>"/>
SOURCE  Raptor Pharmaceutical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 
Related biology technology :

1. Raptor Pharmaceuticals Schedules 2009 Annual Meeting of Stockholders
2. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
3. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
4. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
5. Raptor Pharmaceuticals Closes $10 Million Private Placement
6. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
7. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
8. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
9. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
10. Raptor Pharmaceuticals Acquires Orphan Clinical Program
11. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast